Baxter International (BAX) stock had a bullish inflow of $23.73 million worth of trades on uptick and an outflow of $15.34 million in downticks on Monday. The total uptick to downtick ratio stood at 1.55. The net money flow into the stock was $8.39 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $8.59 million. An inflow of $2.1 million block trade was recorded on downticks. $10.68 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. The total uptick to downtick ratio of block trades was 5.1 in favor of the bulls. However, Baxter International (BAX) stock traded down $0.18 , and reached $48.41, a drop of -0.37% over the previous day. On a weekly basis, the stock is 0.73%, over the previous weeks close.
Shares of Baxter International Inc. rose by 0.9% in the last five trading days and 3.51% for the last 4 weeks. Baxter International Inc. is up 6.79% in the last 3-month period. Year-to-Date the stock performance stands at 27.64%.
Baxter International (NYSE:BAX): The stock opened at $48.70 on Monday but the bulls could not build on the opening and the stock topped out at $48.98 for the day. The stock traded down to $48.39 during the day, due to lack of any buying support eventually closed down at $48.41 with a loss of -0.37% for the day. The stock had closed at $48.59 on the previous day. The total traded volume was 2,312,297 shares.
In a related news, Almeida Jose E, CEO of Baxter International Inc had purchased 11,691 shares on May 23, 2016 in a transaction. The price per share was $42.75 and the total amount of the disclosed transaction was $499,790.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.